Results 201 to 210 of about 5,637 (225)

Modulation of IRF7-driven transcription as a strategy to control HIV-1 latency. [PDF]

Front Immunol
Ezeonwumelu IJ, Garcia-Vidal E, Felip E, Cabrero-de Las Heras S, Clotet B, Badia R, Ballana E, Riveira-Muñoz E, Nevot M.   +8 more
europepmc   +1 more source

Latent HIV Reservoirs in the Central Nervous System: Mechanisms, Barriers, and Therapeutic Approaches. [PDF]

ACS Infect Dis
Matthew Y, Foley N, Claiborne DT, Klase Z, Dick A.   +4 more
europepmc   +1 more source

Block-and-Lock Approaches for HIV Cure: Mechanistic Insights, Challenges, and Emerging Role of CPSF6. [PDF]

Int J Mol Sci
Tolomeo M, Cascio A.
europepmc   +1 more source

Astragalus polysaccharide promotes latent HIV-1 reactivation via exosome-mediated modulation of the PI3K/AKT/NF-κB axis. [PDF]

Extracell Vesicles Circ Nucl Acids
Xu F, Luo S, Lu P, Wang Y, Sun G, Li C, Li W.   +6 more
europepmc   +1 more source

Shocking HIV-1 with immunomodulatory latency reversing agents [PDF]

Seminars in Immunology, 2021
The "shock-and-kill" strategy is one of the most explored HIV-1 cure approaches to eliminate latent virus. This strategy is based on HIV-1 reactivation using latency reversing agents (LRAs) to reactivate latent proviruses (the "shock" phase) and to induce subsequent elimination of the reactivated cells by immune responses or virus-induced cytopathic ...
Gilles Darcis, Anna Kula-Pacurar, Carine Van Lint   +2 more
exaly   +5 more sources

The Current Status of Latency Reversing Agents for HIV-1 Remission [PDF]

Annual Review of Virology, 2021
Combinatory antiretroviral therapy (cART) reduces human immunodeficiency virus type 1 (HIV-1) replication but is not curative because cART interruption almost invariably leads to a rapid rebound of viremia due to the persistence of stable HIV-1-infected cellular reservoirs.
Gilles Darcis, Anthony Rodari
exaly   +4 more sources

T cell toxicity of HIV latency reversing agents

Pharmacological Research, 2019
Combination antiretroviral therapy reduces morbidity and mortality in HIV infected patients. However, the cure of HIV infection is hindered by the persistence of the latent HIV reservoir. Latency reversing agents (LRAs) are developed to target the HIV latently infected cells for HIV reactivation.
Teun Van Gelder, Peter Katsikis, Manzhi Zhao   +2 more
exaly   +3 more sources

Latency-reversing agents: where are we now? [PDF]

Current Opinion in HIV and AIDS
Purpose of review Despite effective antiretroviral therapy (ART), HIV-1 persists in latently infected cells that evade host immunity and can resume viral production upon treatment interruption. To address this challenge, the “shock and kill” strategy aims to use latency-reversing agents (LRAs) to reactivate HIV ...
Bendoumou, Maryam, Van Lint, Carine
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

HIV latency reversal agents: A potential path for functional cure?

European Journal of Medicinal Chemistry, 2021
Despite the advances in Human Immunodeficiency Virus (HIV) treatment, the cure for all HIV patients still poses a major challenge, which needs to be surpassed in the coming years. Among the strategies pursuing this aim, the 'kick-and-kill' approach, which involves the reactivation and elimination of a latent HIV reservoir that resides in some CD4+ T ...
Juliana Romano Lopes, Diego Eidy Chiba, Jean Leandro Dos Santos   +2 more
openaire   +2 more sources

Advances in structure-activity relationships of HDAC inhibitors as HIV latency-reversing agents

Expert Opinion on Drug Discovery
HIV-infected cells may rebound due to the existence of the silent HIV-infected memory CD4+ T cells (HIV latency). This HIV latency makes the disease almost incurable. In latency, the integrated proviral DNA of HIV is transcriptionally silenced partly due to the activity of histone deacetylases (HDACs).
Shovanlal Gayen, Tarun Jha, Sk Abdul Amin   +2 more
exaly   +3 more sources